Delisting riskPopularity #4,824
ENDRA Life Sciences (NDRA)
Developing radio-frequency thermoacoustic ultrasound for point-of-care liver-fat measurement.
$6.00
vs last close−0.31 (−4.91%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Insiders | 31.76% | 403.4K shares | |
|---|---|---|---|
| 5 holders · as of Mar 4, 2026 | |||
| Strategic holders | 0.00% | 6 shares | |
| 1 holder · as of Feb 14, 2019 | |||
| Other | 68.24% | 866.7K shares | |
| remainder | |||
1.27M company shares as of Sep 12, 2026 · holders as of their latest filing
Two share counts disagree (1.50M in the company's Sep 22, 2026 report, 1.27M elsewhere); stakes use the report.
13F
No 13F holders on record.
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| John Carter Lipman | 9.99% | 115.5K | 13G | Oct 30, 2025 |
| Anthony DiGiandomenico | 9.90% | 196.7K | 13D | Jun 29, 2026 |
| ATW Master Fund V LP | 9.90% | 116.0K | 13G | Oct 28, 2025 |
Form 4
Latest trades
No open-market trades in the last 12 months.
House and Senate disclosures
Not reported.
